A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
BACKGROUND
Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin.


METHODS
Eligibility criteria included incurable ACC, any number of prior therapies but without an anthracycline, unidimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and ejection fraction within normal limits. Patients with stable disease for ≥9 months were excluded. Patients received bortezomib 1.3 mg/m(2) by intravenous (IV) push on Days 1, 4, 8, and 11, every 21 days until progression. Doxorubicin 20 mg/m(2) IV on Days 1 and 8 was added at the time of progression.


RESULTS
Twenty-five patients were enrolled, of whom 24 were eligible; the most common distant metastatic sites were the lung (n = 22) and the liver (n = 7). There was no objective response with single-agent bortezomib; best response was stable disease in 15 (71%) of 21 evaluable patients. The median progression-free survival and overall survival were 6.4 months and 21 months, respectively. Of 10 evaluable patients who received bortezomib plus doxorubicin, 1 had a partial response, and 6 had stable disease. The most frequent toxicity with bortezomib was grade 3 sensory neuropathy (16%). With bortezomib plus doxorubicin, serious toxicities seen more than once were grade 3-4 neutropenia (n = 3) and grade 3 anorexia (n = 2).


CONCLUSIONS
Bortezomib was well tolerated and resulted in disease stabilization in a high percentage of patients but no objective responses. The combination of bortezomib and doxorubicin was also well tolerated and may warrant further investigation in ACC.
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA. argirisae@upmc.edu
Athanassios
A
Argiris
Musie
M
Ghebremichael
Barbara
B
Burtness
Rita S
RS
Axelrod
Ronald C
RC
Deconti
Arlene A
AA
Forastiere
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D016019:Survival Analysis
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D004317:Doxorubicin
Clin Cancer Res. 2003 Mar;9(3):1136-44
12631619
Exp Cell Res. 1999 Jul 10;250(1):213-22
10388535
J Clin Oncol. 2006 Jun 10;24(17):2673-8
16763282
Ann Oncol. 1996 Aug;7(6):640-2
8879381
Cancer Chemother Pharmacol. 2008 Dec;63(1):109-15
18322686
Clin Cancer Res. 2005 Oct 15;11(20):7334-43
16243805
Oral Oncol. 2009 Jul;45(7):574-8
18804410
J Clin Oncol. 2007 Sep 1;25(25):3978-84
17761983
Ann Oncol. 1993 Nov;4(9):785-8
8280659
Cell Prolif. 2009 Apr;42(2):150-61
19317804
Blood. 2003 Mar 15;101(6):2377-80
12424198
Oral Oncol. 2007 Jan;43(1):33-6
16757202
Clin Cancer Res. 1999 Sep;5(9):2638-45
10499643
Clin Otolaryngol Allied Sci. 1997 Oct;22(5):434-43
9372255
Bull Cancer. 1998 Oct;85(10):892-4
9835866
Oral Oncol. 2003 Oct;39(7):724-7
12907212
Head Neck. 2006 Mar;28(3):197-204
16470745
Am J Surg. 1997 Nov;174(5):495-8
9374223
Cancer. 1980 Aug 1;46(3):452-4
6249480
Cancer. 2001 Feb 1;91(3):541-7
11169936
Oral Oncol. 2001 Feb;37(2):185-92
11167147
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Ann Oncol. 1996 Oct;7(8):867-9
8922205
J Clin Oncol. 2005 Jan 20;23(3):585-90
15659505
Ann Oncol. 2008 Jun;19(6):1160-5
18326520
Cancer. 1987 Dec 15;60(12):2869-72
2824016